Pharmaceutical Technology, January 2024

January 03, 2024

Revolutionary therapies restructure pharmaceutical manufacturing.

January 03, 2024

European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.

January 03, 2024

There are positive indications for future growth.

January 03, 2024

A thoughtfully constructed QRM Master Plan translates the strategy and enables a risk-based approach.

January 03, 2024

Novel molecular glues are transforming targeted protein degradation.

January 03, 2024

Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.

January 03, 2024

Designers adopt value-added features, different materials, and enhanced coding technologies.

January 03, 2024

UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.

January 02, 2024

Analytical methods and tools play a pivotal role in cleaning validation.

January 02, 2024

The EHDS aims to increase access to health data, but how will it impact pharma?

January 02, 2024

Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.

January 02, 2024

GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.

January 02, 2024

Reviewing regulatory documents, such as 483 forms and Warning Letters, can aid in determining a facility’s inspection readiness, says Siegfried Schmitt, vice president, Technical at Parexel.

January 02, 2024

Galbraith Laboratories, a Bureau Veritas Company, offers a full range of analytical services for pharma, from R&D to final release testing.

January 02, 2024

ROSS Mixers, a provider of US-designed and manufactured mixing equipment, offers a Trial Rental Program, giving process managers an opportunity to optimize R&D projects before committing to a substantial investment.